Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Other Non Operating Income: 2019-2025

Historic Other Non Operating Income for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $16.5 million.

  • BridgeBio Pharma's Other Non Operating Income rose 816.03% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 200.11%. This contributed to the annual value of -$26.6 million for FY2024, which is 253.08% down from last year.
  • BridgeBio Pharma's Other Non Operating Income amounted to $16.5 million in Q3 2025, which was up 151.39% from $6.5 million recorded in Q2 2025.
  • BridgeBio Pharma's Other Non Operating Income's 5-year high stood at $28.3 million during Q4 2021, with a 5-year trough of -$26.6 million in Q1 2024.
  • Its 3-year average for Other Non Operating Income is -$620,100, with a median of $437,500 in 2023.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first slumped by 7,700.00% in 2021, then spiked by 1,136.08% in 2025.
  • BridgeBio Pharma's Other Non Operating Income (Quarterly) stood at $28.3 million in 2021, then plummeted by 83.88% to $4.6 million in 2022, then spiked by 377.59% to $21.8 million in 2023, then soared by 134.01% to $1.8 million in 2024, then surged by 816.03% to $16.5 million in 2025.
  • Its last three reported values are $16.5 million in Q3 2025, $6.5 million for Q2 2025, and -$21.2 million during Q1 2025.